Compelling Efficacy and Safety Data for Orsiro Hybrid Drug-Eluting Stent Presented during EuroPCR Hotline Session
BIOTRONIK today announced results establishing non-inferiority of the Orsiro hybrid drug-eluting stent (DES) to the Reso…
BIOTRONIK today announced results establishing non-inferiority of the Orsiro hybrid drug-eluting stent (DES) to the Reso…
BIOTRONIK announced today the first patient enrolment in the BIOSTEMI trial. The randomized, controlled superiority tria…
One Year Data from Industry-Independent SORT OUT VII Trial Presented at EuroPCR 2015 Reveals Orsiro Is Non-Inferior to N…
BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, today hosted a scientific symposium re…
BIOTRONIK, a leading manufacturer of cardiovascular medical technology, today announced the market release of Orsiro, th…
The BIOTRONIK Stent is the only Vascular Intervention Product Featured in this Year's ESC Hot Line Sessions. Late-bre…